Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry"

Transcription

1 Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is comprised of companies involved in the research, development, manufacturing, marketing, and selling of ethical drugs. In 2008, the global pharmaceuticals industry generated $615.1 billion in total revenues with the United States market generating $273.9 billion, or 44% of the global market. Pharmaceuticals also continue to experience positive growth, demonstrating a CAGR of 4.7% from (Appendix 1). While the industry generates healthy revenues, it is heavily concentrated within the top ten firms who accounted for more than half, $348.3 billion, of total global revenues in (Appendix 2) A trend within the pharmaceutical industry that has been developing over the past 10 years is an increase in advertising and promotional expenditures, which doubled the amount spent for R&D in the United States in As seen in Appendix 3, there are three main areas of promotional spending; however, there is one category that has seen a high growth rate in spending relative to the others since Direct to Consumer advertising (DTC) which grew 330% from $985 million in 1996 to $4,237 million in Although the DTC growth rate is relatively high compared to other promotional categories it only comprised 14% of promotional spending in Direct to Consumer Advertising DTC is one method of promotion in pharmaceuticals, but what types of advertising fall under the category of DTC? The two primary avenues are television and the Internet with the bulk of expenditures falling under television advertisements. The industry has seen a dramatic increase within this segment of promotion and many speculate that the growth was a direct result of the FDA relaxing regulations of 1 Wood, Laura. "Research and Markets: Global Top 10 Pharmaceutical Companies - Generated Total Revenues of $348.3 Billion During 2008 Reuters." Reuters.com - World News, Financial News, Breaking US & International News. Reuters, 24 July Web. 20 Oct < 2 Shaw, Amy. "Direct-to-Consumer Advertising of Pharmaceuticals, ProQuest Discovery Guides." CSA. Mar Web. 22 Oct < 3 Donohue, Julie M., Marissa Cevasco, and Meredith Rosenthal. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." The New England Journal of Medicine, 16 Aug Web. 21 Oct < 1

2 DTC advertising in Previously, pharmaceutical companies had to list the drug s brand name and the benefits on a television commercial along with the associated risks. This led to ineffective advertisements for companies; however, when this restriction was eliminated, companies could begin to run reminder ads. These ads advertise the brand name of the drug and offer a referral website or information phone number so consumers can get more information. These types of advertisements also are exempt from risk disclosure requirements. 2 DTC advertising is attractive to pharmaceutical companies because of its ability to easily reach millions of consumers and introduce them to the product with little regulation involved. Pros & Cons of DTC The increase in DTC advertising has had large effects on the industry and pharmaceutical consumers. While many call the increased spending detrimental to the U.S. health care system, the pharmaceutical industry is quick to point out the benefits of increased DTC spending. These benefits include: increased public awareness of potential health issues and methods of treatment, better dialog with a physician through increased patient power and making the condition seem less embarrassing, and the ability to make more informed decisions through DTC advertisements and websites. 2 On the other hand, doctors and many studies seem to be split on the beneficial effects of DTC advertising. FDA surveys conducted in 1999 and 2002 found 53% of physicians believed DTC advertisements resulted in better discussions with patients and 42% of physicians believed patients were made more aware of available treatments. 4 Studies of the effect of advertising on prescribing practices have shown such advertising increases sales, helps to prevent underuse of medicines to treat chronic conditions, and at the same time, leads to some overuse of prescription drugs. 3 Some groups, such as the American College of Physicians, are more starkly against DTC advertising contending it may upset the doctor-patient relationship 5 or create a demand for prescription drugs that may not be appropriate. 6 Critics also claim physicians are often forced to take time to explain why a treatment seen on TV is not appropriate or physicians may feel pressure to prescribe drugs to accommodate the patient's request. 7 This can be especially damaging in light of revelations regarding 4 Rados, C. (2004). "Truth in Advertising: Rx Drug Ads Come of Age." FDA consumer 38(4), pp Spake, D.F. and Mathew, J. (2007). Consumer opinion and effectiveness of direct-to-consumer advertising. Journal of Consumer Marketing 24(5), pp Huh, J., Langteau, R. (2007). Presumed influence of DTC prescription drug advertising: Do experts and novices think differently? Communication Research. 34(1) pp Metzl, Jonathan M. (2007). If Direct-to-Consumer Advertisements Come to Europe: Lessons from the USA. Lancet 369(9562), pp

3 drug safety. Clinical trials required for drug approval are usually not designed to detect rare but significant adverse effects. This was seen in the case of Vioxx (rofecoxib), a drug heavily promoted to consumers that was later found to increase the risk of heart attacks. 3 In addition to potential detrimental effects of DTC advertising on doctors and patients it may also increase the monetary burden of the U.S. health care system. A Kaiser Foundation study found every $1 the pharmaceutical industry spent on DTC advertising in that year yielded an additional $4.20 in drug sales. In 2000, DTC advertising was responsible for 12% of the increase in prescription drugs sales, or an additional $2.6 billion. 8 Often times newer and more heavily advertised drugs tend to be more expensive than generic drugs or older versions of a given medication. One example of this is Avandia and Actos that treat Type 2 Diabetes and were found to be no more safe or effective than older drugs, but are much more expensive. 9 Another study found that compared with newer drugs such as Zyprexa, Seroquel, and Risperdal, older medication was found to be just as effective and up to $600 cheaper per month. 10 Along with an increase in DTC spending there has been an increase in the time it takes the FDA to issue regulatory letters asking the drug company to take specific actions in regards to DTC complaints. From the FDA letters cited advertisements for either minimizing risks, exaggerating effectiveness or both. In 2006, the Government Accountability Office criticized the FDA on behalf of U.S. Senators after the time it took to issue a regulatory letter rose from an average of two weeks from 1997 to 2001 to an average of four months from 2002 to 2005 (Appendix 4). In addition, the number of regulatory letters dropped from 142 in 1997 to 21 in One reason for this decline is the small number of staff members who review advertisements while DTC advertising continues to grow substantially. 3 This understaffing poses an issue since drug companies are not required to submit their ads before mass distribution, even though they are required to submit their final set of advertisements to the FDA. 2 The gap of time between catching errors in misleading advertisements that have been widely distributed can lead to a costly fix for pharmaceutical companies which is passed on to consumers. 8 "Impact of Direct-to-Consumer Advertising on Prescription Drug Spending - Kaiser Family Foundation." The Henry J. Kaiser Family Foundation - Health Policy, Media Resources, Public Health Education & South Africa - Kaiser Family Foundation. Web. 25 Oct < 9 CR Report. (2007). 10 Vedantam, S. (2006, Dec 1). Cost Benefits of New Schizophrenia Drugs Doubted; Older Medication, Considered Equally Effective, Can Be as Much as $600 a Month Cheaper, Study Finds. The Washington Post, pp. A.9. 3

4 Motivation for Increased DTC Spending Despite continued criticism of DTC advertising, pharmaceutical companies continue to increase the number of advertisements. If negative sentiments and complaints are surrounding DTC advertising, what are the motivating factors for drug companies to continually plaster screens with advertisements? The answer lies in increasing sales revenue, looming patent expiration dates for many large company s cash cow drugs, and the threat of generic drugs. A key motivating factor, which is linked to a company s revenue, is the approaching patent expiration dates for key drugs and the dramatic price cut that will inevitably follow due to generics entering the market. For example, a year after Zantac s patent expired prices had dropped to 15% of the pre-patent amount and to 10% the following year due to generic entry into the market. 11 Generics are a growing concern for large pharmaceutical companies who center their strategies on high revenues generated by branded, patent protected drugs. After the passing of the Drug Price Competition and Patent Term Restoration Act in 1984, generics took a larger share of the market jumping from 18.6% to 54% in Drugs losing their patent protection in 2000 resulted in an annual revenue reduction of $6.5 billion along with future cumulative losses. 11 The threat of generics and the end of patent exclusivity is a strong motivator for large pharmaceutical industries to increase promotional efforts. While companies still enjoy patent protection, they want to increase revenues from a drug by generating interest in the initial years of the drug s release. Also, by creating a brand identity with consumers through DTC advertising, companies are hoping branding will reduce losses that will occur once generics enter the market and drive down prices. This trend in the industry results in an increase in DTC advertising and promotions as a whole, despite continued criticism and increasing costs for pharmaceutical companies. Conclusion Healthcare costs continue to rise and pharmaceutical companies continue to increase their costs that ultimately get passed down to consumers. Currently, large pharmaceutical companies would lose market share and revenues if they cut back advertising. From a game theory standpoint the increases in advertising may be compared to a prisoner s dilemma. Rival companies are spending more money on a 11 Berndt, Ernst R. "The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment? -- Berndt 20 (2): Health Affairs." Health Affairs: The Policy Journal of the Health Sphere. Web. 22 Oct < 4

5 relatively stable population to gain market share. Conversely it may be beneficial for all large Pharma companies to decrease DTC advertising in order to maintain the current level of competition while reducing cost. When Congress banned cigarette advertising in 1970 earnings at the major cigarette producers were up 30% in 1971 as compared to 1970 by eliminating the advertising rivalry which did not greatly affect sales. In an industry with increasing political controversy, decreasing healthcare costs for consumers will be a priority for large pharmaceutical companies who wish to remain competitive within a changing industry. 5

6 Appendix 1: Global Pharmaceuticals Market Value: $ Billion Datamonitor, Global Pharmaceutical Industry Appendix 2: Pharmaceutical Industry s Concentration Top Ten Firms Revenue Rank Company Country Total revenues ($bn) 1 Pfizer U.S. $ Johnson & Johnson U.S. $ GlaxoSmithKline United Kingdom $ Bayer Germany $ Hoffmann-La Roche Switzerland $ Sanofi-Aventis France $ Novartis Switzerland $ AstraZeneca UK/Sweden $ Abbott Laboratories U.S. $ Merck & Co. U.S. $ Total Revenues $ Source: Top 50 Pharmaceutical Companies Charts & Lists, Med Ad News, September

7 Appendix 3: Direct-to-Consumer Advertising and Promotion to Health Professionals, Source: Donohue, Julie M., Marissa Cevasco, and Meredith Rosenthal. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." The New England Journal of Medicine, 16 Aug Web. 21 Oct < Appendix 4: Complaints and Regulatory Letters Written Concerning DTC Advertising Source: Donohue, Julie M., Marissa Cevasco, and Meredith Rosenthal. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." The New England Journal of Medicine, 16 Aug Web. 21 Oct < 7

Impact of Direct-to-Consumer Advertising on Prescription Drug Spending

Impact of Direct-to-Consumer Advertising on Prescription Drug Spending Impact of Direct-to-Consumer Advertising on Prescription Drug Spending June 2003 The Kaiser Family Foundation is an independent, national health philanthropy dedicated to providing information and analysis

More information

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry

More information

PRESCRIPTION DRUGS: BACKGROUND AND BASICS

PRESCRIPTION DRUGS: BACKGROUND AND BASICS PRESCRIPTION DRUGS: BACKGROUND AND BASICS Medicare & Medicaid Briefings National Health Policy Forum January 30, 2009 Jim Hahn Congressional Research Service PRESCRIPTION DRUGS FAQS What is the price of

More information

Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366

Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 1.0 Executive Summary 2.0 Situation Analysis 2.1 Market Summary 2.1.1 Market Demographics 2.1.2 Market Needs 2.1.3 Market Trends

More information

Why Are Drugs So Expensive? Learning About the Drug Development Process

Why Are Drugs So Expensive? Learning About the Drug Development Process Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal

More information

The Covario SEO Audit Score Industry Rankings. The Pharmaceutical Industry

The Covario SEO Audit Score Industry Rankings. The Pharmaceutical Industry The Covario SEO Audit Score Industry Rankings The Pharmaceutical Industry Direct-to-consumer advertising is the fastest-growing form of marketing in the pharmaceutical industry. Outpacing the growth of

More information

DIRECT-TO-CONSUMER ADVERTISING IN THE PHARMACEUTICAL INDUSTRY: AN ANALYSIS OF INFORMATION DISPARITIES

DIRECT-TO-CONSUMER ADVERTISING IN THE PHARMACEUTICAL INDUSTRY: AN ANALYSIS OF INFORMATION DISPARITIES DIRECT-TO-CONSUMER ADVERTISING IN THE PHARMACEUTICAL INDUSTRY: AN ANALYSIS OF INFORMATION DISPARITIES Young, Mallory A. Cornell University Eckrich, Donald Ithaca College ABSTRACT This paper analyzes the

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente?

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? 57 Congresso Nazionale SIGG Società Italiana di Gerontologia e Geriatria Dr. Marco Scatigna Direttore Medico e

More information

55 What are the rules for promoting medications to consumers in the U.S.?

55 What are the rules for promoting medications to consumers in the U.S.? Chapter 55 What are the rules for promoting medications to consumers in the U.S.? The U.S. and New Zealand are the only two countries that allow the directto-consumer (DTC) advertising of prescription

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Anthony Genovese Bayer HealthCare October 9, 2014

Anthony Genovese Bayer HealthCare October 9, 2014 Anthony Genovese Bayer HealthCare October 9, 2014 Disclaimer The view and opinions expressed here today are the views of the author and do not necessarily reflect the official policy or position of Bayer.

More information

Reducing Waste with an Efficient Medicare Prescription Drug Benefit

Reducing Waste with an Efficient Medicare Prescription Drug Benefit Issue Brief January 2013 Reducing Waste with an Efficient Medicare Prescription Drug Benefit BY DEAN BAKER* When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that

More information

Data Trends Report. Encuity. Testosterone Replacement Therapy

Data Trends Report. Encuity. Testosterone Replacement Therapy Encuity Data Trends Report Encuity has cost-effective solutions to suit your business needs through our various syndicated services. Encuity Data Trends Report provides insight on how our collective services

More information

I ve been asked to talk about the Pharmaceutical Benefits Scheme in the context of Medicare and the broader health sector.

I ve been asked to talk about the Pharmaceutical Benefits Scheme in the context of Medicare and the broader health sector. 1 Sustaining the PBS for the future Dr Brendan Shaw, Chief Executive, Medicines Australia Speech to 2 nd Future of Medicare Conference 11 November 2010, Sydney Thank you for the opportunity to speak with

More information

Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING

Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING West Virginia Title 210 LEGISLATIVE RULE GOVERNOR S OFFICE OF HEALTH ENHANCEMENT AND LIFESTYLE PLANNING (GOHELP) Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING 210-1-1. General. 1.1. Scope. --

More information

The NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005

The NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005 EMBARGOED FOR RELEASE 6 p.m. EST, June 2 Summary The NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005 An Analysis by Consumers Union and Consumer Reports Best Buy Drugs June 2005 Doctors

More information

Pharmaceutical Marketing and Research Spending: The Evidence Does Not Support PhRMA s Claims

Pharmaceutical Marketing and Research Spending: The Evidence Does Not Support PhRMA s Claims Pharmaceutical Marketing and Research Spending: The Evidence Does Not Support PhRMA s Claims Deborah Socolar, MPH, and Alan Sager, PhD Directors, Health Reform Program Boston University School of Public

More information

New Multi-Marketing Channel Strategies

New Multi-Marketing Channel Strategies Brochure More information from http://www.researchandmarkets.com/reports/1082161/ New Multi-Marketing Channel Strategies Description: The future of Pharma marketing lies in using new marketing channels

More information

Prescription drug costs continue to rise at

Prescription drug costs continue to rise at Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge

More information

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

More information

Pharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story

Pharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy 20 July 2014 Terminology

More information

The Cost of Irrational

The Cost of Irrational The Cost of Irrational Medicine Use Margaret Ewen Coordinator, Global Projects (Pricing) Health Action International (HAI) Global Amsterdam PPRI Conference September 2011 Irrational medicine use is widespread

More information

Monetary and Political Effects of Product Liability Lawsuits in. the Pharmaceutical Industry. Constructed By: Spenser Hanson.

Monetary and Political Effects of Product Liability Lawsuits in. the Pharmaceutical Industry. Constructed By: Spenser Hanson. Monetary and Political Effects of Product Liability Lawsuits in the Pharmaceutical Industry Constructed By: Spenser Hanson Joe Wadle October 24 th, 2009 G400: Professor Andreas Hauskrecht Introduction

More information

Healthcare, Regulatory and Reimbursement Landscape - Australia

Healthcare, Regulatory and Reimbursement Landscape - Australia Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape

More information

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors

More information

Great Expectations: Why Pharma Companies Can t Ignore Patient Services

Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Life Sciences Rethink Reshape Restructure... for better patient outcomes Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Research Note: Key findings from a survey

More information

The Factors Fueling Rising Health Care Costs 2008

The Factors Fueling Rising Health Care Costs 2008 The Factors Fueling Rising Health Care Costs 2008 Prepared for America s Health Insurance Plans, December 2008 2008 America s Health Insurance Plans Table of Contents Executive Summary.............................................................2

More information

Fact Sheet. Prescription Data Mining

Fact Sheet. Prescription Data Mining November 19, 2008 Fact Sheet Prescription Data Mining The Prescription Project promotes evidence-based prescribing and works to eliminate conflicts of interest in medicine due to pharmaceutical marketing

More information

Understanding Prescription Assistance Programs (PAPs)

Understanding Prescription Assistance Programs (PAPs) Understanding Prescription Assistance Programs (PAPs) The use of prescription medicines has become an increasingly important part of quality medical care. Two out of every three visits to the doctor end

More information

PRESCRIPTION MEDICINES: COSTS IN CONTEXT

PRESCRIPTION MEDICINES: COSTS IN CONTEXT PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise

More information

U.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA

U.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA Page 35 U.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA Guy W. Giorno, Lynne Golding, Vincent Routhier, and Philippe David Fasken Martineau DuMoulin LLP INTRODUCTION Legislation currently before

More information

Direct-to-Consumer Advertising (DTC) of Pharmaceuticals by Amy Shaw

Direct-to-Consumer Advertising (DTC) of Pharmaceuticals by Amy Shaw Introduction Discovery Guides Direct-to-Consumer Advertising (DTC) of Pharmaceuticals by Amy Shaw A popular sleep advertisement shows an unshaven insomniac at a kitchen table with Abe Lincoln and a talking

More information

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com

More information

Rising Health Care Costs What Factors are Driving Increases?

Rising Health Care Costs What Factors are Driving Increases? Rising Health Care Costs What Factors are Driving Increases? Rising health care costs and access to affordable coverage are prominent issues for Washington employers, health care providers, purchasers,

More information

The Impact of Prescription Drug Prices on Seniors

The Impact of Prescription Drug Prices on Seniors The Impact of Prescription Drug Prices on Seniors Over the years medicine has changed, particularly with respect to prescription drugs: more drugs are available, they are more frequently prescribed, and

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

Setting the Record Straight about Medicare

Setting the Record Straight about Medicare Fact Sheet Setting the Record Straight about Medicare Keith D. Lind, JD, MS As the nation considers the future of Medicare, it is important to separate the facts from misconceptions about Medicare coverage,

More information

An Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements

An Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements An Examination of Consumer Perceptions of Direct to Consumer Prescription Drug Advertisements And Implications for Current Food and Drug Administration Oversight of Direct to Consumer Advertisement Regulations

More information

Altering Medical Relationships by Pharmaceutical Advertising to the Public

Altering Medical Relationships by Pharmaceutical Advertising to the Public Altering Medical Relationships by Pharmaceutical Advertising to the Public Nowhere within this discussion do I wish to argue that a patient should have information denied from them, however clearly advertising

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

BARACK OBAMA S PLAN FOR A HEALTHY AMERICA:

BARACK OBAMA S PLAN FOR A HEALTHY AMERICA: BARACK OBAMA S PLAN FOR A HEALTHY AMERICA: Lowering health care costs and ensuring affordable, high-quality health care for all The U.S. spends $2 trillion on health care every year, and offers the best

More information

Big Data and Healthcare Information. Ed Reiner Quintiles Transnational

Big Data and Healthcare Information. Ed Reiner Quintiles Transnational Big Data and Healthcare Information Ed Reiner Quintiles Transnational About Me 30 years in the information sector McGraw-Hill Information Division Elsevier Science (Cardiosource, ScienceDirect) Medical

More information

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director

Can India be the Leader in Global Generics. Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Can India be the Leader in Global Generics Rtn. J. Jayaseelan.,B.Pharm., M.B.A., Managing Director Indian Pharma Industry Before 1970 Depending on MNC from USA and Europe for supply of Medicines Hardly

More information

Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry

Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry July 2014 FOR FURTHER INFORMATION, PLEASE CONTACT: John Mangano comscore, Inc. +1 (703) 438-2358 jmangano@comscore.com

More information

Specialty Drug Hyperinflation:

Specialty Drug Hyperinflation: Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System Specialty drugs 1 offer important hope for many patients with complex, hard-to-treat illnesses. While the price of specialty

More information

TABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition

TABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition TABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition SUMMARY OF SALIENT POINTS Importance and Competitiveness of the Ethical Pharmaceutical Industry Government

More information

Healthcare Insurance Industry: A Global View

Healthcare Insurance Industry: A Global View KPJ National Healthcare Conference 2005 9 December, 2005 Putrajaya, MY Healthcare Insurance Industry: A Global View Presented by: Hank Kearney PHM 2005 PHM Congratulations KPJ Healthcare Berhad on 25 years

More information

Health Policy 201 drugs. Ellen Andrews, PhD Fall 2011

Health Policy 201 drugs. Ellen Andrews, PhD Fall 2011 Health Policy 201 drugs Ellen Andrews, PhD Fall 2011 benefits Since the mid-1990s, when researchers developed a new wave of medicines to treat HIV/AIDS, the U.S. death rate from AIDS dropped about 70 percent.

More information

When investigative sites are struggling with subject recruitment, and it

When investigative sites are struggling with subject recruitment, and it PEER REVIEWED When investigative sites are struggling with subject recruitment, invariably, someone will propose paying noninvestigator physicians for referrals, while others will be adamant in their opposition

More information

Pharma Promotional Spending in 2013

Pharma Promotional Spending in 2013 May 2014 Vol. 13, No. 5 Pharma Marketing Network www.pharmamarketingnews.com Pharma Promotional Spending in 2013 Professional Detailing, edetailing, DTC Advertising, Professional Meetings, Journal Advertising

More information

Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015

Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015 Life Sciences Industry in Canada Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015 Life Sciences in Canada Canadian life sciences

More information

Solo Practice/Urgent Care Clinic

Solo Practice/Urgent Care Clinic Solo Practice/Urgent Care Clinic A Case Study by Rebuild Nation PROBLEM A solo practice recently opened a clinic in a new market. Costs were increasing while patients were decreasing month-to-month. The

More information

When treating a disease is bad business: orphan and neglected diseases

When treating a disease is bad business: orphan and neglected diseases When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the

More information

Global Pharmaceuticals Marketing Channel Reference EDITION

Global Pharmaceuticals Marketing Channel Reference EDITION Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry

More information

NCCI examined the cost and use of prescription drugs in workers compensation in order to answer the following key questions:

NCCI examined the cost and use of prescription drugs in workers compensation in order to answer the following key questions: Prescription Drugs: Comparison of Drug Costs and Patterns of Use in Workers Compensation and Group Health Plans Overview In recent years, the costs for pharmaceuticals rose more rapidly than any other

More information

ISSUE BRIEF. Pharmaceutical Discounts for Medicare Beneficiaries Can Save Seniors Money. September 2002

ISSUE BRIEF. Pharmaceutical Discounts for Medicare Beneficiaries Can Save Seniors Money. September 2002 Pharmaceutical Discounts for Medicare Beneficiaries Can Save Seniors Money Prescription Drug Gap in Medicare The majority of people over 65 in the United States have coverage for medical care through the

More information

AND STILL GET HIGH QUALITY CARE?

AND STILL GET HIGH QUALITY CARE? HOW CAN WE REDUCE OUR HEALTH CARE SPENDING AND STILL GET HIGH QUALITY CARE? A Choicework discussion guide from Public Agenda, developed through a collaborative research project with the Kettering Foundation

More information

Direct-to-Consumer Advertising of Prescription Drugs: Exposure and Response

Direct-to-Consumer Advertising of Prescription Drugs: Exposure and Response Direct-to-Consumer Advertising of Prescription Drugs: Exposure and Response November 2010 Direct-to-Consumer Advertising of Prescription Drugs: Exposure and Response Report Prepared by Helen Brown COPYRIGHT

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers

Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Brief submitted by The New Brunswick Nurses Union April 2012 Background The New Brunswick

More information

The Industry. Johnson and Johnson is involved in the health care industry. through three distinct business segments: consumer, medical, and

The Industry. Johnson and Johnson is involved in the health care industry. through three distinct business segments: consumer, medical, and 1 Johnson and Johnson Analysis Andrew West and The Industry Johnson and Johnson is involved in the health care industry through three distinct business segments: consumer, medical,

More information

When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses. November 13, 2002 Washington, DC

When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses. November 13, 2002 Washington, DC When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses November 13, 2002 Washington, DC These materials were commissioned by the Robert Wood Johnson Foundation for use

More information

Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation

Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust

More information

The Unintended Effects of

The Unintended Effects of The Unintended Effects of Healthcare Reform TOM SUROVY, PRINCIPLE COMPLIANCE ATTORNEY CONTENTS CHILD-ONLY POLICIES... 3 PRESCRIPTIONS FOR NONPRESCRIPTION OVER-THE-COUNTER DRUGS... 4 COMMISSIONS FOR INSURANCE

More information

Medicare part d, which offers

Medicare part d, which offers Trends The Effects Of The Coverage Gap On Drug Spending: A Closer Look At Medicare Part D Beneficiaries who entered the doughnut hole decreased their monthly prescriptions by about percent per month. by

More information

Chairman Craig, Senator Breaux, distinguished Committee members, thank you for inviting me

Chairman Craig, Senator Breaux, distinguished Committee members, thank you for inviting me Chairman Craig, Senator Breaux, distinguished Committee members, thank you for inviting me to discuss the consequences of direct to consumer advertising (DTCA) of prescription drugs. I have been asked

More information

Global Policy on Interactions with Healthcare Professionals

Global Policy on Interactions with Healthcare Professionals Global Policy on Interactions with Healthcare Professionals Global Policy on Interactions with Healthcare Professionals Pfizer is committed to collaborating with physicians and other healthcare professionals,

More information

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

Generic substitution of prescription drugs

Generic substitution of prescription drugs Generic substitution of prescription drugs Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (2)2003 Author(s): Ilmo Keskimäki and Lauri Vuorenkoski

More information

Focus Areas. Historical Development. Historical Development. Historical Development. Pharmaceutical Industry THE PHARMACEUTICAL INDUSTRY: AN OVERVIEW

Focus Areas. Historical Development. Historical Development. Historical Development. Pharmaceutical Industry THE PHARMACEUTICAL INDUSTRY: AN OVERVIEW THE PHARMACEUTICAL INDUSTRY: AN OVERVIEW Focus Areas Thomas Reinders, Pharm.D. Associate Dean School of Pharmacy Smith Bldg, Room 14 tpreinde@mail2.vcu.edu Wed. August 4 th, 24. 8 am 9 am. Brief historical

More information

Paul Appelbaum, Julio Arboleda-Flórez, Afzal Javed, Constantin Soldatos, Sam Tyano. WPA Standing Committee on Ethics

Paul Appelbaum, Julio Arboleda-Flórez, Afzal Javed, Constantin Soldatos, Sam Tyano. WPA Standing Committee on Ethics for relationships of psychiatrists, health care organizations working in the psychiatric field and psychiatric associations with the pharmaceutical industry Paul Appelbaum, Julio Arboleda-Flórez, Afzal

More information

Information in Direct-to-Consumer

Information in Direct-to-Consumer Experimental Study of Quantitative Benefit Information in Direct-to-Consumer Prescription Drug Advertising i Presented by Doug Rupert, MPH; Amie O Donoghue, PhD; Dhuly Chowdhury, MS, MBA; Helen Sullivan,

More information

Health Care Job Information Sheet #20. Clinical Research

Health Care Job Information Sheet #20. Clinical Research Health Care Job Information Sheet #20 Clinical Research A. Background B. Occupations 1) Clinical Research Associate (Study Monitor) 2) Clinical Research Coordinator 3) Other positions in the field C. Labour

More information

The facts about rising health care costs Underlying medical costs drive growth

The facts about rising health care costs Underlying medical costs drive growth Quality health plans & benefits Healthier living Financial well-being Intelligent solutions The facts about rising health care costs Underlying medical costs drive growth October 2012 00.03.966.1-L11 A

More information

IMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS

IMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. IMPACT OF

More information

LITIGATION FUNDING FREQUENTLY ASKED QUESTIONS

LITIGATION FUNDING FREQUENTLY ASKED QUESTIONS LITIGATION FUNDING FREQUENTLY ASKED QUESTIONS 1. WHAT IS THE LITIGATION FUNDING PROGRAM? In simple terms, it is a mutually agreed upon contract between a legal marketing firm and another party, a Funder.

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

WHAT IS THE NATURE OF THE HEALTHCARE CHALLENGE FACING SOUTH FLORIDA?

WHAT IS THE NATURE OF THE HEALTHCARE CHALLENGE FACING SOUTH FLORIDA? WHAT IS THE NATURE OF THE HEALTHCARE CHALLENGE FACING SOUTH FLORIDA? South Florida is a dynamic community defined by its diverse population, which includes large groups of senior citizens and immigrants.

More information

Medicine and the Pharmaceutical Industry - How Did We Get Here? Where Are We Going?

Medicine and the Pharmaceutical Industry - How Did We Get Here? Where Are We Going? Medicine and the Pharmaceutical Industry - How Did We Get Here? Where Are We Going? Deborah Way, MD, CMD LIFE University of Pennsylvania School of Nursing Pamela Fenstemacher, MD, CMD LIFE at Home Faculty

More information

Medicare Advantage and Part D Fraud, Waste, and Abuse Training. October 2010

Medicare Advantage and Part D Fraud, Waste, and Abuse Training. October 2010 Medicare Advantage and Part D Fraud, Waste, and Abuse Training October 2010 Introduction 2008: United States spent $2.3 trillion on health care. Federal fiscal year 2010: Medicare expected to cover an

More information

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the

More information

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements

More information

BIOPHARMACEUTICAL INDUSTRY IMPACT REPORT: Florida PRESENTED BY:

BIOPHARMACEUTICAL INDUSTRY IMPACT REPORT: Florida PRESENTED BY: BIOPHARMACEUTICAL INDUSTRY IMPACT REPORT: Florida PRESENTED BY: About the report About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country s leading innovative

More information

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug

More information

Pharmaceutical Policy in Korea: Role of Health Insurance in Pricing, Reimbursement and Monitoring

Pharmaceutical Policy in Korea: Role of Health Insurance in Pricing, Reimbursement and Monitoring Pharmaceutical Policy in : Role of Health Insurance in Pricing, Reimbursement and Monitoring Soonman KWON* and Sukyeong KIM** *Dean, School of Public Health Seoul National University ** Director, Research

More information

TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.

TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1. 1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed

More information

Strategic Alliance as an Alternative Strategy for Bio-ventures

Strategic Alliance as an Alternative Strategy for Bio-ventures Strategic Alliance as an Alternative Strategy for Bio-ventures Seiichiro Yonekura, Professor Shiaw Jia Eyo, PhD Candidate Institute of Innovation Research Presentation Outline IPO Model Might Not Work

More information

GAO PRESCRIPTION DRUGS. Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising. Report to Congressional Requesters

GAO PRESCRIPTION DRUGS. Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising. Report to Congressional Requesters GAO United States Government Accountability Office Report to Congressional Requesters November 2006 PRESCRIPTION DRUGS Improvements Needed in FDA s Oversight of Direct-to-Consumer Advertising GAO-07-54

More information

Battle for the market: Branded drug companies secret weapons generic drug makers must know

Battle for the market: Branded drug companies secret weapons generic drug makers must know Battle for the market: Branded drug companies secret weapons generic drug makers must know Received (in revised form): 28 th March, 2005 Jon Hess is a senior analyst and consulting project leader with

More information

Leveraging Social Media for Pharmaceutical Companies

Leveraging Social Media for Pharmaceutical Companies Leveraging Social Media for Pharmaceutical Companies Realized by Synthesio Summary Introduction.2 Social media and the new health paradigm.3 Millions of online consumer conversations to explore.4 Detecting

More information

ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study. Dr. Scott Neslin May 22, 2001

ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study. Dr. Scott Neslin May 22, 2001 ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study Dr. Scott Neslin May 22, 2001 Study Objectives! Measure ROI for detailing (DET), direct-to-consumer advertising (DTC), medical journal

More information

Improved Medicare for All

Improved Medicare for All Improved Medicare for All Quality, Guaranteed National Health Insurance by HEALTHCARE-NOW! Single-Payer Healthcare or Improved Medicare for All! The United States is the only country in the developed world

More information

Consensus Model for APRN Regulation (2008) Methods Design Measurement of State Regulation of Practice of APRNs

Consensus Model for APRN Regulation (2008) Methods Design Measurement of State Regulation of Practice of APRNs Sonenberg A. Examining Current State Nurse Practitioner Regulatory Policies: Their Potential Impact on Health Care Access. In: Seminário Nacional de Pesquisa em Enfermagem, 17, 2013 jun 3 5. Anais. Natal:

More information

WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing

More information

FDA Regulation of Pharmaceutical Marketing. Tom Casola Executive Director Commercial Operations Merck & Co., Inc.

FDA Regulation of Pharmaceutical Marketing. Tom Casola Executive Director Commercial Operations Merck & Co., Inc. FDA Regulation of Pharmaceutical Marketing Tom Casola Executive Director Commercial Operations Merck & Co., Inc. Brief History of Rx Drug Regulation 1931- Food & Drug Administration Established 1938 -

More information

New York State Assembly, District 61

New York State Assembly, District 61 2007 AARP Voters Guide New York State Assembly, District 61 How to use the AARP Voters Guide: Here s how this Voters Guide works. AARP asked key questions about issues important to our members and their

More information

CAN-SPAM Act Rulemaking, Project No. R411008

CAN-SPAM Act Rulemaking, Project No. R411008 1301 K Street NW Suite 900 East Tower Washington DC 20005-3317 Telephone 202 230 5619 Facsimile 202 230 5300 June 27, 2005 By Hand Federal Trade Commission Office of the Secretary, Room H-159 600 Pennsylvania

More information

Group insurance. Generic drugs. Their positive effect on your wallet

Group insurance. Generic drugs. Their positive effect on your wallet Group insurance Generic drugs Their positive effect on your wallet A wise choice Prescription drugs have a couple of things in common: they re designed to heal us or make us feel better, and most of them

More information

Improved Medicare for All

Improved Medicare for All Take Action: Get Involved! The most important action you can take is to sign up for Healthcare-NOW! s email list, so you can stay connected with the movement and get updates on organizing efforts near

More information